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Abstract
Objective: To determine whether the improved precision of nuchal translucency (NT) measurement used in antenatal
screening for Down’s syndrome observed over time as evidenced by a decrease in the multiple of the median (MoM) standard
deviation requires a modification to the NT MoM truncation limits to maintain accurate risk estimation.
Methods: Probability plots were derived from the measurements of NT MoM values used in a 2018 audit of 22,362 unaffected
pregnancies. The plots were used to determine whether the NT MoM upper truncation limit should be lowered. Validation
plots were used to assess the screening accuracy of Down’s syndrome risk estimates calculated from observed NT
MoM values in the 22,362 unaffected pregnancies and 69 Down’s syndrome pregnancies for original and revised NT MoM
truncation limits.
Results: Probability plots indicated that with improved precision of NT measurements, there was deviation from a Gaussian
distribution at less high MoM values than with less precise measurements. Validation plots showed that using the current NT
MoM upper truncation limit of 2.5 MoM with improved precision NT measurements overestimates the Down’s syndrome risk
(median risk in highest risk category expressed as an odds was 53.3:1 and observed prevalence was 1:1.1). The large discrep-
ancy was corrected by changing the NTupper truncation limit to 2.0 MoM (median risk in highest risk category expressed as an
odds was 1:1.78 and observed prevalence 1:2.7).
Conclusion: The NT MoM upper truncation limit should be reduced from 2.5 to 2.0 MoM.
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Introduction
Measurement of nuchal translucency (NT) is an important
marker in antenatal screening for Down’s syndrome, tri-
somy 18 and trisomy 13. Over time, the precision of mea-
suring NT has improved leading to a reduction in the
standard deviation. For example, at 12 completed weeks’
gestation, the log10 NT MoM (multiple of the median)
standard deviation was 0.1329, 0.1105 and 0.0855 in
2003,1 20102 and 2018,3,4 respectively, as reported from
the Wolfson Institute Screening Service. The distribution
of NT is positively skewed; after log transformation, the
distribution is reasonably Gaussian, but there is still a
degree of positive skew.5 To deal with screening markers
deviating from Gaussian distributions in the tails of the
distributions, it is standard practice to specify truncation
limits in which values above or below these limits are
assigned values at the truncation limits.6,7
As NT measurement has become more precise, there is
a case for lowering the upper truncation limit from the
2.5 MoM value2 set in 2010 to take account of the posi-
tively skewed distribution of log-transformed NT MoM
values. We here examined data from the Wolfson
Institute of Preventive Medicine Antenatal Screening
Programme to determine whether there was a need to
revise the NT upper truncation limit.
1Logical Medical Systems Ltd, London, UK
2Wolfson Institute of Preventive Medicine, Barts and the London School of
Medicine and Dentistry, Queen Mary University of London, London, UK
3UCL Institute of Health Informatics, London, UK
Corresponding author:
Nicholas J Wald, UCL Institute of Health Informatics, London NW1 2DA, UK.
Email: n.wald@ucl.ac.uk
J Med Screen
2021, Vol. 28(2) 88–92






Data from a 2018 audit of antenatal screening were used
based on measurements from 22,362 unaffected singleton
pregnancies and 69 Down’s syndrome pregnancies.8
A probability plot was generated for the NT MoM
values and inspected to determine if the upper truncation
limits should be lowered from the currently specified value
of 2.50 MoM.2 A term Down’s syndrome risk estimate was
calculated from the NT measurements for each of the
22,362 unaffected singleton pregnancies and 69 affected
singleton pregnancies. The risk estimates were calculated
by previously described standard methods9 from the over-
lapping log10 NT MoM Gaussian distributions of affected
and unaffected pregnancies, using published sets of NT
distribution parameters2,4,10 (see Appendix 1), the
observed overall Down’s syndrome prevalence in the
sample population and the currently specified NT upper
truncation limits of 2.50 MoM and 2.0 MoM.
To assess the accuracy of risk estimation using the two
NT upper truncation limits, validation plots11,12 were cre-
ated in which the risk estimates were ranked and put into
seven categories with approximately equal numbers of
affected pregnancies in each category. Within each catego-
ry, the median risk and the observed prevalence of Down’s
syndrome were calculated. The accuracy of risk estimation
is displayed by plotting the median risk against the
observed prevalence in each category. Points lying close
to the diagonal line of identity (where predicted risk
equals observed prevalence) indicate the accuracy of risk
estimation.
Statistical analyses were performed using RStudio
(RStudio Team (2019). RStudio: Integrated
Development for R. RStudio, Inc., Boston, MA URL
http://www.rstudio.com/). NT MoM values calculated at
the time of screening with the Alpha software (Logical
Medical Systems, London, UK) were used.
Results
Figure 1 shows the NT MoM probability plot. Deviation
from a log-Gaussian distribution is apparent at an NT
measurement of about 2.0 MoM rather than 2.5 MoM.
Figure 2(a) and (b) shows validation plots for Down’s
syndrome risk estimates calculated using the current NT
upper truncation limits of 2.5 MoM and 2.0 MoM, respec-
tively. Table 1 gives the numerical results shown in
Figure 2(a) and (b). When the NT upper truncation limit
is 2.5 MoM, the risk estimates are inaccurate at high risks
(greater than about 1 in 10). In the highest risk category,
over 50 times more affected pregnancies are predicted than
observed: the predicted risk estimate and the observed
prevalence, expressed as an odds (affected:unaffected)
are 53.1:1 and 1:1.1, respectively.
Reducing the NT upper truncation limit to 2.0 MoM
brings the plotted points closer to the diagonal line of
identity and thereby improves the accuracy of the risk
estimates. With an upper truncation limit of 2.0 MoM in
the highest risk category, the predicted risk estimate and
the observed prevalence (both expressed as an odds) are
1:1.78 and 1:2.7, respectively.
Discussion
This study shows that the NTMoM upper truncation limit
should be revised from 2.5 to 2.0 MoM as a result of the
improved prevision of NT measurements over time. The
less high upper truncation limit improves the accuracy of
risk estimation in antenatal screening for Down’s syn-
drome. Retaining the 2.5 MoM upper truncation limit
overestimates risk estimation for pregnancies with high
NT MoM values. Although such pregnancies would prob-
ably be screen-positive, a truncation limit of 2.0 MoM
avoids an excess of very high inaccurate risk estimates
among women with screen-positive results.
Figure 1. Probability plot of NT measurements in unaffected pregnancies from 2018 study.8 The two horizontal lines show the positions of
the NT upper truncation limits at 2.0 and 2.5 MoM.
MoM: multiple of the median.
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The distribution of NT log10 MoMs is positively
skewed, so that the distribution of NT measurements at
higher MoM values (those above about 2.0 MoM) is not
well estimated by a Gaussian distribution (applicable to
about 0.4% of unaffected pregnancies). With a
smaller standard deviation, the expected number of preg-
nancies with high NT MoMs is substantially less than
that observed. Consequently, the likelihood ratio calculat-
ed from the overlapping Gaussian distributions of
affected and unaffected pregnancies at high NT MoMs
will be overestimated, and hence the risk of having
an affected pregnancy will be overestimated. This is illus-
trated in the validation plot of Figure 2(a) where the NT
MoM upper truncation limit is set at 2.5 MoM, which
Figure 2. Validation plots for Down’s syndrome risk estimates expressed as probabilities (1 in x) calculated using NT measurements from
the 2018 audit,8 with the current reduced unaffected NT standard deviation.4 (a) Validation plot with NTupper truncation limit of 2.5 MoM.
(b) Validation plot with NT upper truncation limit of 2.0 MoM. (The points plotted in the two highest risk categories are nearly
superimposed.).
Table 1. Numerical results for the validation plot in Figure 2.
Predicted risk Observed
Median Prevalence
Category Probability Odds Down’s Syndrome Unaffected Proportion Odds
(a) NT upper truncation limit¼ 2.5 MoM
>1 in1.0195 1 in 1.0188 53.3:1 10 11 1 in 2.1 1:1.1
1 in 1.0195– 1 in 1.166 6.0:1 10 62 1 in 7.2 1:6.2
1 in 1.26– 1 in 12.0 1:11.0 10 180 1 in 19.0 1:18.0
1 in 35.4– 1 in 141.2 1:140.2 10 630 1 in 64.0 1:63.0
1 in 245– 1 in 472 1:471 10 1571 1 in 158 1:157
1 in 658– 1 in 1077 1:1076 10 4439 1 in 445 1:444
<1 in1352 1 in 1816 1:1815 9 15469 1 in 1720 1:1719
All 1 in 1661 1:1660 69 22362 1 in 325 1:324
(b) NT upper truncation limit¼ 2.0 MoM
>1 in 2.7864 1 in 2.7831 1:1.7831 10 27 1 in 3.7 1:2.7
1 in 2.7864– 1 in 2.796 1:1.796 10 30 1 in 4.0 1:3.0
1 in 2.91– 1 in 10.7 1:9.7 10 196 1 in 20.6 1:19.6
1 in 35.4– 1 in 141.2 1:140.2 10 630 1 in 64.0 1:63.0
1 in 245– 1 in 472 1:471 10 1571 1 in 158 1:157
1 in 658– 1 in 1077 1:1076 10 4439 1 in 445 1:444
<1 in 1352 1 in 1816 1:1815 9 15,469 1 in 1720 1:1719
All 1 in 1661 1:1660 69 22,362 1 in 325 1:324
NT: nuchal translucency; MoM: multiple of the median.
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shows how the error is limited to women with the highest
risk estimates.
Figure 3 shows a partial histogram of NT MoM values
(between 1.5 and 3.0 MoM) in unaffected pregnancies. The
figure also shows the proportions using a Gaussian distri-
bution with and without truncation at 2.0 MoM. With an
NT upper truncation limit of 2.0 MoM, the truncated NT
distribution fits the observed data reasonably well, illus-
trating how it leads to improved accuracy of risk
estimation.
Revising the NT upper truncation limit from 2.5 MoM
to 2.0 MoM will not reduce the detection rate because the
effect is limited to pregnancies with very high risk esti-
mates (greater than about 1 in 10) that would anyway be
classified as screen positive. It, however, avoids the over-
estimation of risk among some pregnancies with the high-
est risk estimates and being limited in this way is robust to
centre-to-centre variation in NT precision.
The improvement in the accuracy of risk estimation
using a less high NT upper truncation limit of 2.0 MoM
will apply to screening for trisomy 18 and trisomy 13 as
well as for Down’s syndrome because the over estimation
of risk for high NT MoM values arises from the persis-
tence of right skewness in the distribution of log10 NT
MoM values in unaffected pregnancies.
In conclusion, the NT MoM upper truncation limit
should be revised from 2.5 to 2.0 MoM when used with
the smaller NT standard deviation associated with the
improved precision of current NT measurements.
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Figure 3. Partial histogram of NT MoM values (between 1.5 and 3.0
MoM) in unaffected pregnancies from the 2018 audit.8 The solid
dotted line shows the Gaussian distribution of NT measurements. To
show a single line, a weighted average for gestational age weeks 10 to
13 was used to calculate the NT MoM standard deviation. The
horizontal line is specified by the truncation limit (2.0 MoM).
MoM: multiple of the median.
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Appendix 1. Summary of published NT distribution parameters.2,4,10
Down’s syndrome pregnancies Unaffected
Median (log10 MoM) 0.8554679–0.0064686 gestational age in days 0.0000
Standard deviation (log10 MoM)
10 completed weeks 0.2313 0.1193a
11 completed weeks 0.0976
12 completed weeks 0.0855
13 completed weeks 0.0855
Lower truncation limits (MoM)
10 completed weeks 0.5
11 completed weeks 0.7
12 completed weeks 0.8
13 completed weeks 0.85
MoM: multiple of the median.
aEstimated from the 10-week standard deviation in Bestwick et al.2 decreased by the reduction in standard deviation at 11 and 12weeks in Wald et al.4
compared to Bestwick et al.2
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